コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 been proposed as another cause of suspected drug-induced liver disease.
2 flammation, hypoxia, hepatic congestion, and drug-induced liver disease.
3 sment remain an important aspect in defining drug-induced liver disease and proposed new upper limits
4 ulties inherent in establishing causality of drug-induced liver disease and the potential negative co
5 emains very involved in the process by which drug-induced liver disease can be detected early in drug
6 orms of liver injury, and several others had drug-induced liver disease confirmed by additional repor
8 drug withdrawals and new general reviews of drug-induced liver disease (DILD), including a review of
9 and first-time reports of various aspects of drug-induced liver disease for several classes of compou
10 se remains low, a large case-series of acute drug-induced liver disease from Spain and Sweden support
12 logical, and epidemiological descriptions of drug-induced liver disease in the calendar year 2004.
13 hold the key to treatment and prevention of drug-induced liver disease in the future and discusses t
14 nisms of injury to predict and avert serious drug-induced liver disease in the future from drugs unde
19 any prescription drugs withdrawn because of drug-induced liver disease, the US Food and Drug Adminis
20 ies, more than half the instances of alleged drug-induced liver disease were found to have other caus
21 as the most commonly reported agents causing drug-induced liver disease, with acetaminophen continuin